Selecta Biosciences to Participate at the H.C. Wainwright Global Investment Conference
Selecta Biosciences, Inc. (NASDAQ: SELB) announced its participation in the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Selecta Biosciences, Inc. (NASDAQ: SELB) announced its participation in the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The company will provide a corporate update and engage in one-on-one investor meetings. The presentation is scheduled for May 24, 2022, at 7:00 a.m. ET. Selecta is focused on developing tolerogenic therapies via its ImmTOR® platform to treat autoimmune diseases and enhance gene therapies. Investors can access a webcast of the presentation and archived materials on their official website.
Details
News Market Reaction – SELB
The recorded move for SELB in the trading session of this news was +9.23%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies and mitigate unwanted immune responses to biologics, today announced that Company’s Management will provide a corporate update and participate virtually in one-on-one investor meetings at the H.C. Wainwright Global Investment Conference, to be held virtually and in Miami, Florida from May 23-26, 2022.
H.C. Wainwright Global Investment Conference
Format: Pre-recorded presentation and one-on-one investor meetings
Date: Tuesday, May 24, 2022
Time: Presentation available at 7:00 a.m. ET
Webcast: Click Here
An archived webcast will also be accessible in the Investors & Media section of the company’s website at www.selectabio.com.
About Selecta Biosciences, Inc.
Selecta Biosciences Inc. (NASDAQ: SELB) is a clinical stage biotechnology company leveraging its ImmTOR® platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. Selecta has several proprietary and partnered programs in its pipeline focused on enzyme therapies, gene therapies, and autoimmune diseases. Selecta Biosciences is headquartered in the Greater Boston area. For more information, please visit www.selectabio.com.
For Investors:
Bruce Mackle
LifeSci Advisors, LLC
+1-929-469-3859
bmackle@lifesciadvisors.com
For Media:
Brittany Leigh, Ph.D.
LifeSci Communications, LLC
+1-646-751-4366
bleigh@lifescicomms.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.